Cargando…
The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-acti...
Autores principales: | Aguilar-Recarte, David, Palomer, Xavier, Wahli, Walter, Vázquez-Carrera, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395240/ https://www.ncbi.nlm.nih.gov/pubmed/34445261 http://dx.doi.org/10.3390/ijms22168555 |
Ejemplares similares
-
Activation of Peroxisome Proliferator–Activated Receptor-β/-δ (PPAR-β/-δ) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6–Stimulated Adipocytes
por: Serrano-Marco, Lucía, et al.
Publicado: (2011) -
PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders
por: Palomer, Xavier, et al.
Publicado: (2018) -
Insights into the Role of PPARβ/δ in NAFLD
por: Chen, Jiapeng, et al.
Publicado: (2018) -
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
por: Zarei, Mohammad, et al.
Publicado: (2017) -
PPARs as Key Mediators in the Regulation of Metabolism and Inflammation
por: Vázquez-Carrera, Manuel, et al.
Publicado: (2022)